A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Former Google CEO Eric Schmidt believes AI's rapid advancement, already handling 10-20% of programming tasks, signals the end ...

Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. Get top stock picks News ...

Here are the top 16 conferences to mark on your 2026 calendar for technologists, business leaders, policy experts, and those ...

Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, British Columbia, Dec. 30, ...

Whether you’re setting out on a course of academic study that will define your professional life, or seeking to build skills to help you land a better job, Santa Clara’s graduate programs offer a ...

Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) -- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine ...